TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer

Poly(ADP-ribose) polymerase (PARP) inhibitors in combination with androgen-receptor signaling inhibitors are a promising therapeutic option for patients with metastatic castration-sensitive prostate cancer (mCSPC) and homologous recombination repair (HRR) gene alterations. Here, we describe the design and rationale of the multinational, phase III, TALAPRO-3 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide in patients with mCSPC and HRR gene alterations. The primary end point is investigator-assessed radiographic progression-free survival (rPFS) per RECIST 1.1 in soft tissue, or per PCWG3 criteria in bone. The TALAPRO-3 study will demonstrate whether the addition of talazoparib can improve the efficacy of enzalutamide as assessed by rPFS in patients with mCSPC and HRR gene alterations undergoing androgen deprivation therapy.Clinical Trial Registration:NCT04821622 (ClinicalTrials.gov)Registry Name: Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC.Date of Registration: 29 March 2021. TALAPRO-3 is a phase III, randomized study that aims to evaluate the efficacy and safety of talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-sensitive prostate cancer (mCSPC) and homologous recombination repair gene alterations.